HR and breast carcinoma: For the first time, these non-TNBC breast cancer samples were similarly found positive for ADAM8: 27.3%, 33.2% and 32.1% for HR−/HER2+, HR+/HER2− and HR+/HER2+ patient samples, respectively (Table 2 and Fig. 3B).